Rates of lobar atrophy in asymptomatic MAPT mutation carriers
Abstract Introduction The aim of this study was to investigate the rates of lobar atrophy in the asymptomatic microtubule‐associated protein tau (MAPT) mutation carriers. Methods MAPT mutation carriers (n = 14; 10 asymptomatic, 4 converters from asymptomatic to symptomatic) and noncarriers (n = 13)...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1016/j.trci.2019.05.010 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849423311746891776 |
|---|---|
| author | Qin Chen Bradley F. Boeve Matthew Senjem Nirubol Tosakulwong Timothy G. Lesnick Danielle Brushaber Christina Dheel Julie Fields Leah Forsberg Ralitza Gavrilova Debra Gearhart Jonathan Graff‐Radford Neill R. Graff‐Radford Clifford R. Jack Jr. David T. Jones David S. Knopman Walter K. Kremers Maria Lapid Rosa Rademakers Jeremy Syrjanen Adam L. Boxer Howie Rosen Zbigniew K. Wszolek Kejal Kantarci LEFFTDS Consortium |
| author_facet | Qin Chen Bradley F. Boeve Matthew Senjem Nirubol Tosakulwong Timothy G. Lesnick Danielle Brushaber Christina Dheel Julie Fields Leah Forsberg Ralitza Gavrilova Debra Gearhart Jonathan Graff‐Radford Neill R. Graff‐Radford Clifford R. Jack Jr. David T. Jones David S. Knopman Walter K. Kremers Maria Lapid Rosa Rademakers Jeremy Syrjanen Adam L. Boxer Howie Rosen Zbigniew K. Wszolek Kejal Kantarci LEFFTDS Consortium |
| author_sort | Qin Chen |
| collection | DOAJ |
| description | Abstract Introduction The aim of this study was to investigate the rates of lobar atrophy in the asymptomatic microtubule‐associated protein tau (MAPT) mutation carriers. Methods MAPT mutation carriers (n = 14; 10 asymptomatic, 4 converters from asymptomatic to symptomatic) and noncarriers (n = 13) underwent structural magnetic resonance imaging and were followed annually with a median of 9.2 years. Longitudinal changes in lobar atrophy were analyzed using the tensor‐based morphometry with symmetric normalization algorithm. Results The rate of temporal lobe atrophy in asymptomatic MAPT mutation carriers was faster than that in noncarriers. Although the greatest rate of atrophy was observed in the temporal lobe in converters, they also had increased atrophy rates in the frontal and parietal lobes compared to noncarriers. Discussion Accelerated decline in temporal lobe volume occurs in asymptomatic MAPT mutation carriers followed by the frontal and parietal lobe in those who have become symptomatic. The findings have implications for monitoring the progression of neurodegeneration during clinical trials in asymptomatic MAPT mutation carriers. |
| format | Article |
| id | doaj-art-449ee00a80f4445289d9ebe809ee80b5 |
| institution | Kabale University |
| issn | 2352-8737 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| spelling | doaj-art-449ee00a80f4445289d9ebe809ee80b52025-08-20T03:30:39ZengWileyAlzheimer’s & Dementia: Translational Research & Clinical Interventions2352-87372019-01-015133834610.1016/j.trci.2019.05.010Rates of lobar atrophy in asymptomatic MAPT mutation carriersQin Chen0Bradley F. Boeve1Matthew Senjem2Nirubol Tosakulwong3Timothy G. Lesnick4Danielle Brushaber5Christina Dheel6Julie Fields7Leah Forsberg8Ralitza Gavrilova9Debra Gearhart10Jonathan Graff‐Radford11Neill R. Graff‐Radford12Clifford R. Jack Jr.13David T. Jones14David S. Knopman15Walter K. Kremers16Maria Lapid17Rosa Rademakers18Jeremy Syrjanen19Adam L. Boxer20Howie Rosen21Zbigniew K. Wszolek22Kejal Kantarci23LEFFTDS Consortium24Department of RadiologyMayo ClinicRochesterMNUSADepartment of NeurologyMayo ClinicRochesterMNUSADepartment of RadiologyMayo ClinicRochesterMNUSADepartment of Health Sciences ResearchMayo ClinicRochesterMNUSADepartment of Health Sciences ResearchMayo ClinicRochesterMNUSAAlzheimer's Disease Research CenterMayo ClinicRochesterMNUSADepartment of NeurologyMayo ClinicRochesterMNUSADepartment of Psychology and PsychiatryMayo ClinicRochesterMNUSADepartment of NeurologyMayo ClinicRochesterMNUSADepartment of Clinical Genomic and NeurologyMayo ClinicRochesterMNUSADepartment of NeurologyMayo ClinicRochesterMNUSADepartment of NeurologyMayo ClinicRochesterMNUSADepartment of NeurologyMayo ClinicJacksonvilleFLUSADepartment of RadiologyMayo ClinicRochesterMNUSADepartment of NeurologyMayo ClinicRochesterMNUSADepartment of NeurologyMayo ClinicRochesterMNUSADepartment of Health Sciences ResearchMayo ClinicRochesterMNUSADepartment of Psychology and PsychiatryMayo ClinicRochesterMNUSAAlzheimer's Disease Research CenterMayo ClinicRochesterMNUSADepartment of Health Sciences ResearchMayo ClinicRochesterMNUSAMemory and Aging Center, University of California San FranciscoSan FranciscoCAUSAMemory and Aging Center, University of California San FranciscoSan FranciscoCAUSADepartment of NeurologyMayo ClinicJacksonvilleFLUSADepartment of RadiologyMayo ClinicRochesterMNUSADepartment of RadiologyMayo ClinicRochesterMNUSAAbstract Introduction The aim of this study was to investigate the rates of lobar atrophy in the asymptomatic microtubule‐associated protein tau (MAPT) mutation carriers. Methods MAPT mutation carriers (n = 14; 10 asymptomatic, 4 converters from asymptomatic to symptomatic) and noncarriers (n = 13) underwent structural magnetic resonance imaging and were followed annually with a median of 9.2 years. Longitudinal changes in lobar atrophy were analyzed using the tensor‐based morphometry with symmetric normalization algorithm. Results The rate of temporal lobe atrophy in asymptomatic MAPT mutation carriers was faster than that in noncarriers. Although the greatest rate of atrophy was observed in the temporal lobe in converters, they also had increased atrophy rates in the frontal and parietal lobes compared to noncarriers. Discussion Accelerated decline in temporal lobe volume occurs in asymptomatic MAPT mutation carriers followed by the frontal and parietal lobe in those who have become symptomatic. The findings have implications for monitoring the progression of neurodegeneration during clinical trials in asymptomatic MAPT mutation carriers.https://doi.org/10.1016/j.trci.2019.05.010Frontotemporal dementiaMagnetic resonance imageMAPTAsymptomaticLongitudinal |
| spellingShingle | Qin Chen Bradley F. Boeve Matthew Senjem Nirubol Tosakulwong Timothy G. Lesnick Danielle Brushaber Christina Dheel Julie Fields Leah Forsberg Ralitza Gavrilova Debra Gearhart Jonathan Graff‐Radford Neill R. Graff‐Radford Clifford R. Jack Jr. David T. Jones David S. Knopman Walter K. Kremers Maria Lapid Rosa Rademakers Jeremy Syrjanen Adam L. Boxer Howie Rosen Zbigniew K. Wszolek Kejal Kantarci LEFFTDS Consortium Rates of lobar atrophy in asymptomatic MAPT mutation carriers Alzheimer’s & Dementia: Translational Research & Clinical Interventions Frontotemporal dementia Magnetic resonance image MAPT Asymptomatic Longitudinal |
| title | Rates of lobar atrophy in asymptomatic MAPT mutation carriers |
| title_full | Rates of lobar atrophy in asymptomatic MAPT mutation carriers |
| title_fullStr | Rates of lobar atrophy in asymptomatic MAPT mutation carriers |
| title_full_unstemmed | Rates of lobar atrophy in asymptomatic MAPT mutation carriers |
| title_short | Rates of lobar atrophy in asymptomatic MAPT mutation carriers |
| title_sort | rates of lobar atrophy in asymptomatic mapt mutation carriers |
| topic | Frontotemporal dementia Magnetic resonance image MAPT Asymptomatic Longitudinal |
| url | https://doi.org/10.1016/j.trci.2019.05.010 |
| work_keys_str_mv | AT qinchen ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT bradleyfboeve ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT matthewsenjem ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT niruboltosakulwong ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT timothyglesnick ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT daniellebrushaber ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT christinadheel ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT juliefields ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT leahforsberg ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT ralitzagavrilova ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT debragearhart ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT jonathangraffradford ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT neillrgraffradford ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT cliffordrjackjr ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT davidtjones ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT davidsknopman ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT walterkkremers ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT marialapid ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT rosarademakers ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT jeremysyrjanen ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT adamlboxer ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT howierosen ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT zbigniewkwszolek ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT kejalkantarci ratesoflobaratrophyinasymptomaticmaptmutationcarriers AT lefftdsconsortium ratesoflobaratrophyinasymptomaticmaptmutationcarriers |